Mitomycin-C is an anticancer antibiotic produced by Streptomyces caespitosus first discovered by Hata et al. at the Kitasato Institute in 1955, and isolated by Wakaki et al. at Kyowa Hakko Kogyo (now Kyowa Hakko Kirin) in the form of purple crystals.
In Japan, the evaluation of its clinical efficacy started in 1957, which has shown that Mitomycin-C is beneficial in the treatment of many types of solid tumors and hematologic malignancies. Based on the clinical evidence, it was approved in 1963 in Japan. And later, it was approved around the world in more than 80 countries.
Marketed by Kyowa Hakko Kirin in
Japan, Korea, Singapore, Taiwan
Marketed by Kyowa Kirin International in
Ireland, Italy, UK, France